{"id":"W3001160691","doi":"10.1200/jco.2018.36.15_suppl.5511","title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Ovarian cancer; Interim; Internal medicine; Clinical endpoint; Interim analysis; Oncology; Cancer; Progression-free survival; Topotecan; Chemotherapy; Surgery; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004500593,0.000985841,0.001126018,0.0002945109,0.0002521062,0.001045661,0.0008204757,0.000959651,0.003312498],"category_scores_gemma":[0.002586624,0.0003954638,0.001182919,0.0003343618,0.0003970556,0.0009419619,0.0005353204,0.002294244,0.000813381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009251204,"about_ca_system_score_gemma":0.001283606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005283698,"about_ca_topic_score_gemma":0.001623165,"domain_scores_codex":[0.9991714,0.0004630305,0.00004902085,0.0001034836,0.00009795652,0.0001151929],"domain_scores_gemma":[0.998435,0.0003492514,0.0005694943,0.0001532614,0.0001015999,0.0003913099],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6386421,0.03741292,0.04426236,0.001980416,0.004188946,0.0004061485,0.0004257719,0.003695019,0.05446075,0.0004344205,0.01716251,0.1969286],"study_design_scores_gemma":[0.4156966,0.4462996,0.1105724,0.0001876067,0.002560755,0.001023808,0.0001216192,0.002390054,0.007585952,0.0005018681,0.01299587,0.00006394646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807011,0.006552407,0.001062478,0.0006314722,0.00008227483,0.002568324,0.004610095,0.0001459354,0.003645868],"genre_scores_gemma":[0.9792801,0.002429391,0.002024357,0.001309723,0.0001551423,0.002335074,0.00999136,0.00004456741,0.00243025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004500593,"threshold_uncertainty_score":0.02380174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08465868098622457,"score_gpt":0.4704217842886687,"score_spread":0.3857631033024441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}